LEADER 03746nam  22006495  450 
001 9910300079603321
005 20200630075916.0
010   $a1-4899-7436-9
024 7 $a10.1007/978-1-4899-7436-5
035   $a(CKB)2560000000147610
035   $a(EBL)1698076
035   $a(OCoLC)876297007
035   $a(SSID)ssj0001204815
035   $a(PQKBManifestationID)11687277
035   $a(PQKBTitleCode)TC0001204815
035   $a(PQKBWorkID)11198528
035   $a(PQKB)10173538
035   $a(MiAaPQ)EBC1698076
035   $a(DE-He213)978-1-4899-7436-5
035   $a(PPN)178317209
035   $a(EXLCZ)992560000000147610
100   $a20140402d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aBone Drugs in Pediatrics $eEfficacy and Challenges /$fedited by Gordon L. Klein
205   $a1st ed. 2014.
210  1$aNew York, NY :$cSpringer US :$cImprint: Springer,$d2014.
215   $a1 online resource (241 p.)
300   $aDescription based upon print version of record.
311   $a1-4899-7435-0 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aIntroduction -- Developmental Pharmacokinetics: Drug Disposition Relative to Age -- Drug Development for Pediatric Diseases with Bone Loss -- Pediatric Bone Physiology and Monitoring Safety and Efficacy of Bone Drugs in Children -- Bisphosphonates in Osteogenesis Imperfecta -- Use of Bisphosphonates in Genetic Diseases Other Than Osteogenesis Imperfecta -- Bisphosphonates in Pediatric Burn Injury -- Growth Hormone and Bone -- Growth Hormone and Oxandrolone in Burned Children -- Pediatric Bone Drugs: Calcium and Vitamin D -- Pediatric Maxillofacial Conditions and Drugs -- Newer Adult Bone Drugs -- Conclusion: Whither (or Wither?) the Pharmacology on Pediatric Bone?.
330   $aBone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves ? such as bisphosphonates, anti-resorptives and anabolic agents ? within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs in future treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.
606   $aEndocrinology
606   $aOrthopedics
606   $aPediatrics
606   $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053
606   $aOrthopedics$3https://scigraph.springernature.com/ontologies/product-market-codes/H45000
606   $aPediatrics$3https://scigraph.springernature.com/ontologies/product-market-codes/H49006
615  0$aEndocrinology.
615  0$aOrthopedics.
615  0$aPediatrics.
615 14$aEndocrinology.
615 24$aOrthopedics.
615 24$aPediatrics.
676   $a610
676   $a616.4
676   $a616.7
676   $a618.92
702   $aKlein$b Gordon L$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300079603321
996   $aBone Drugs in Pediatrics$91521976
997   $aUNINA